US FDA's Bioshield project broaches role and use of medical products in counter-terror actions
This article was originally published in Clinica
Executive Summary
How unapproved medical products might be made available on an emergency basis as counter-measures to combat biological, radiological or chemical warfare is the subject of a new draft guidance document released by the US FDA.